1. Home
  2. SYBX vs NEPH Comparison

SYBX vs NEPH Comparison

Compare SYBX & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYBX
  • NEPH
  • Stock Information
  • Founded
  • SYBX N/A
  • NEPH 1997
  • Country
  • SYBX United States
  • NEPH United States
  • Employees
  • SYBX N/A
  • NEPH N/A
  • Industry
  • SYBX Biotechnology: Pharmaceutical Preparations
  • NEPH Medical/Dental Instruments
  • Sector
  • SYBX Health Care
  • NEPH Health Care
  • Exchange
  • SYBX Nasdaq
  • NEPH Nasdaq
  • Market Cap
  • SYBX 15.9M
  • NEPH 15.4M
  • IPO Year
  • SYBX N/A
  • NEPH 2004
  • Fundamental
  • Price
  • SYBX $1.44
  • NEPH $1.59
  • Analyst Decision
  • SYBX Buy
  • NEPH Buy
  • Analyst Count
  • SYBX 4
  • NEPH 1
  • Target Price
  • SYBX $15.50
  • NEPH $5.00
  • AVG Volume (30 Days)
  • SYBX 11.6K
  • NEPH 8.1K
  • Earning Date
  • SYBX 11-12-2024
  • NEPH 11-07-2024
  • Dividend Yield
  • SYBX N/A
  • NEPH N/A
  • EPS Growth
  • SYBX N/A
  • NEPH N/A
  • EPS
  • SYBX N/A
  • NEPH N/A
  • Revenue
  • SYBX $2,777,000.00
  • NEPH $13,546,000.00
  • Revenue This Year
  • SYBX N/A
  • NEPH N/A
  • Revenue Next Year
  • SYBX N/A
  • NEPH $7.39
  • P/E Ratio
  • SYBX N/A
  • NEPH N/A
  • Revenue Growth
  • SYBX 292.23
  • NEPH 0.03
  • 52 Week Low
  • SYBX $1.22
  • NEPH $1.36
  • 52 Week High
  • SYBX $5.12
  • NEPH $4.04
  • Technical
  • Relative Strength Index (RSI)
  • SYBX 52.54
  • NEPH 54.85
  • Support Level
  • SYBX $1.37
  • NEPH $1.39
  • Resistance Level
  • SYBX $1.42
  • NEPH $1.61
  • Average True Range (ATR)
  • SYBX 0.08
  • NEPH 0.05
  • MACD
  • SYBX -0.00
  • NEPH 0.01
  • Stochastic Oscillator
  • SYBX 29.24
  • NEPH 71.43

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.

Share on Social Networks: